Inavolisib Combination Delays Chemotherapy by 2 Years in PIK3CA-Mutant Breast Cancer

Why Does It Matter?

Among patients with hormone-sensitive (HR+), HER2-negative advanced breast cancer, approximately 35–40% have a PIK3CA mutation . These mutations are associated with a worse disease course but are also important biomarkers of increased sensitivity to PI3K inhibitors. However, resistance to current treatments is common, and survival remains below the desired level.

Against this background, the new targeted PI3Kα inhibitor inavolisibhas demonstrated significant improvements in both progression-free and overall survival when used first line with palbociclib (a CDK4/6 inhibitor) and fulvestrant (endocrine therapy).

New Evidence Supporting FDA Approval

These striking findings are not entirely surprising, because inavolisib, in October 2024, received US Food and Drug Administration (FDA) approvalfor use with palbociclib and fulvestrant in patients with hormone receptor-positive (HR+), HER2-negative, PIK3CA-mutated, endocrine-resistant advanced breast cancer . This accelerated approval was based on early INAVO120 analyses demonstrating a significant progression-free survival (PFS) benefit. At that time, however, overall survival (OS) data were not yet mature. Now, presented at ASCO 2025 and simultaneously published in NEJM, the final analysishas strongly supported this FDA approval by showing that the combination not only suppresses the disease, but also significantly prolongs survival .

The INAVO120 Study: Design and Participants

• Patient profile: Endocrine-resistant, PIK3CA-mutated, HR+/HER2- advanced breast cancer.
• Randomization: 325 patients (161 in the inavolisib arm, 164 in the placebo arm).
• Treatment combination:
  • Inavolisib 9 mg PO once daily (days 1–28)
  • Palbociclib 125 mg PO once daily (days 1–21)
  • Fulvestrant 500 mg IM (days 1 and 15, then every 28 days)

Overall Survival (OS): An Additional 7 Months

• Median overall survival:
  • Inavolisib group: 34.0 months
  • Placebo group: 27.0 months
  • HR: 0.67 (95% CI: 0.48–0.94), p = 0.019
• 12-month survival rate:
  • Inavolisib: 87.0%
  • Placebo: 76.7%

💡 This difference is considered not only statistically significant, but also clinically meaningful .

Progression-Free Survival (PFS): A 10-Month Advantage

• Median PFS:
  • Inavolisib: 17.2 months
  • Placebo: 7.3 months
  • HR: 0.42 (95% CI: 0.32–0.55)

Objective Response Rate (ORR): A Twofold Increase

• Response rate:
  • Inavolisib group: 62.7%
  • Placebo group: 28.0%
  • p < 0.0001

Time to Chemotherapy: Delayed by 2 Years

• Time to chemotherapy (TTC):
  • Inavolisib: 35.6 months
  • Placebo: 12.6 months
  • HR: 0.43

🎯 This finding is important because it shows how much more effective first-line control can delay the transition to chemotherapy.

Safety Profile: Expected Class Effects

• Grade 3–4 adverse events:
  • Inavolisib group: 90.7%
  • Placebo group: 84.7%
• Hyperglycemia (any grade):
  • Inavolisib: 63.4%
  • Placebo: 13.5%
• Mucositis/stomatitis:
  • Inavolisib: 55.3%
  • Placebo: 28.8%
• Ocular toxicities (blurred vision, dry eye):
  • Inavolisib: 29.2%
  • Placebo: 16.0%

❗ The treatment-related discontinuation rate remained at only 6.8%, indicating that the drug is tolerable over the long term .

Other Findings and Interpretation

• Adverse event management: Control is possible through strategies such as dose reductions and treatment interruptions.
• Comparative success: The SOLAR-1 study of alpelisib did not demonstrate an overall survival benefit. INAVO120 represents a first in this respect.
• Clinical implication: In PIK3CA-mutated advanced HR+ breast cancer, inavolisib + palbociclib + fulvestrant could become a new standard .

Conclusion

INAVO120 has demonstrated the powerful results achievable with rational targeted combinations. In PIK3CA-mutated HR+ HER2– advanced breast cancer, a first-line triple combination produced a significant survival gain . Adverse events reflect class effects, and treatment continuation rates are high when these events are managed well. This may mark the beginning of a new era for patients and clinicians.